ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with ...
Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments ...
Jessica Shurer, Director of Clinical Affairs and Advocacy at CurePSP, has been appointed to the National Parkinson's Project (NPP) Advisory Council on Parkinson's Research, Care and Services -- ...
Add Yahoo as a preferred source to see more of our stories on Google. TERRE HAUTE, Ind. (WTWO/WAWV) — Indiana American Water announced plans to build a $19 million advanced drinking water treatment ...
Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meeting FDA and Novo ...
A Laotian refugee with terminal cancer missed chemotherapy while in ICE custody, leading to deteriorating health and hospice care. US embassy issues urgent terrorist attack warning: 'Leave immediately ...
An immigrant with an aggressive form of cancer who was previously in ICE custody is now in hospice after missing several chemotherapy sessions. Oudone Lothirath, a Laotian refugee who arrived in the U ...
Please provide your email address to receive an email when new articles are posted on . The impact of early disease is prompting more aggressive therapies. BTK ...
Cell-of-origin (GCB/ABC) and 7 genetic subgroups inform targeted strategies, yet R‑CHOP remains frontline; 30%–40% relapse or are refractory with poor salvage outcomes post-rituximab. Second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results